A director at EBOS Group sold 143,692 shares at 36.638NZD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
The general evaluation of EBOS GROUP (NZ), a company active in the Drug Retailers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 29, 2022, the closing price was NZD 40...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Another test of support Heightened trade tensions have caused global equities to move from resistance to support in a matter of days. Additional consolidation - i.e., no breakdowns - on the broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) remains the most likely scenario. At the same time, new cracks are beginning to show and as a result we believe global equities are vulnerable to a breakdown. • New cracks emerging. Breakdowns in crude oil and new lows for the STOXX 600 Bank super...
Global equities nearing potential resistance Helped by support from global central banks and improving trade headlines, critical support levels have held for major global indexes and therefore our outlook remains constructive. At the same time, just because these indexes are not breaking down does not mean they are headed higher. Rather, we believe global equities remain in a state of purgatory and consolidation is likely to continue as several major indexes approach logical resistance... see c...
We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below ou...
We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below ou...
Ebos operates a conglomerate business offering a range of products and services targeting the healthcare and animal-care markets in both Australia and New Zealand. Ebos has grown primarily via acquisitions during the past 13 years. Its transformational Symbion acquisition in 2013 propelled Ebos to the second-largest and most diversified pharmaceutical wholesaler and the largest hospital distributor in the Australian market. Ebos Group's narrow economic moat rating is predicated on the efficient ...
Ebos operates a conglomerate business offering a range of products and services targeting the healthcare and animal-care markets in both Australia and New Zealand. Ebos has grown primarily via acquisitions during the past 13 years. Its transformational Symbion acquisition in 2013 propelled Ebos to the second-largest and most diversified pharmaceutical wholesaler and the largest hospital distributor in the Australian market. Ebos Group's narrow economic moat rating is predicated on the efficient ...
We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below our...
We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below our...
Ebos operates a conglomerate business offering a range of products and services targeting the healthcare and animal-care markets in both Australia and New Zealand. Ebos has grown primarily via acquisitions during the past 13 years. Its transformational Symbion acquisition in 2013 propelled Ebos to the second-largest and most diversified pharmaceutical wholesaler and the largest hospital distributor in the Australian market. Ebos Group's narrow economic moat rating is predicated on the efficient ...
We have remodelled key assumption drivers and changed our forecasts to Australian dollars from New Zealand dollars to align with Ebos' recent change of reporting currency. These modelling changes, combined with updating forecasts following fiscal 2019 first-half results, lifted our valuation to AUD 20 (NZD 21 per share using a spot AUD/NZD exchange rate of 1.04) from AUD 19. We lowered the five-year revenue compound annual growth rate to 5% from 6% to reflect the subdued pharmaceutical distribut...
We have remodelled key assumption drivers and changed our forecasts to Australian dollars from New Zealand dollars to align with Ebos' recent change of reporting currency. These modelling changes, combined with updating forecasts following fiscal 2019 first-half results, lifted our valuation to AUD 20 (NZD 21 per share using a spot AUD/NZD exchange rate of 1.04) from AUD 19. We lowered the five-year revenue compound annual growth rate to 5% from 6% to reflect the subdued pharmaceutical distribut...
We have remodelled key assumption drivers and changed our forecasts to Australian dollars from New Zealand dollars to align with Ebos' recent change of reporting currency. These modelling changes, combined with updating forecasts following fiscal 2019 first-half results, lifted our valuation to AUD 20 (NZD 21 per share using a spot AUD/NZD exchange rate of 1.04) from AUD 19. We lowered the five-year revenue compound annual growth rate to 5% from 6% to reflect the subdued pharmaceutical distribut...
We have remodelled key assumption drivers and changed our forecasts to Australian dollars from New Zealand dollars to align with Ebos' recent change of reporting currency. These modelling changes, combined with updating forecasts following fiscal 2019 first-half results, lifted our valuation to AUD 20 (NZD 21 per share using a spot AUD/NZD exchange rate of 1.04) from AUD 19. We lowered the five-year revenue compound annual growth rate to 5% from 6% to reflect the subdued pharmaceutical distribut...
We have remodelled key assumption drivers and changed our forecasts to Australian dollars from New Zealand dollars to align with Ebos' recent change of reporting currency. These modelling changes, combined with updating forecasts following fiscal 2019 first-half results, lifted our valuation to AUD 20 (NZD 21 per share using a spot AUD/NZD exchange rate of 1.04) from AUD 19. We lowered the five-year revenue compound annual growth rate to 5% from 6% to reflect the subdued pharmaceutical distribut...
We have remodelled key assumption drivers and changed our forecasts to Australian dollars from New Zealand dollars to align with Ebos' recent change of reporting currency. These modelling changes, combined with updating forecasts following fiscal 2019 first-half results, lifted our valuation to AUD 20 (NZD 21 per share using a spot AUD/NZD exchange rate of 1.04) from AUD 19. We lowered the five-year revenue compound annual growth rate to 5% from 6% to reflect the subdued pharmaceutical distribut...
Following our trip to narrow-moat Ebos' first investor day and the visit to its new Symbion distribution centre in Brisbane, we maintain our fair value estimate of NZD 20 per share (AUD 19 per share using the spot exchange rate of 1.07). Despite ongoing headwinds from the group's pharmacy distribution business, we believe improving cost efficiency and diversification into pet care and consumer brands will support overall profitability, and we expect Ebos' EBIT margin to remain at around 3.2% for...
Following our trip to narrow-moat Ebos' first investor day and the visit to its new Symbion distribution centre in Brisbane, we maintain our fair value estimate of NZD 20 per share (AUD 19 per share using the spot exchange rate of 1.07). Despite ongoing headwinds from the group's pharmacy distribution business, we believe improving cost efficiency and diversification into pet care and consumer brands will support overall profitability, and we expect Ebos' EBIT margin to remain at around 3.2% for...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.